Jump to content

IVX-411

From Wikipedia, the free encyclopedia

IX-411
Vaccine description
TargetSARS-CoV-2
Vaccine typeVirus-like particles
Clinical data
Routes of
administration		Intramuscular

IVX-411is a COVID-19 candidatenanoparticlevaccine under development byIcosavaxcurrently undergoing a Phase I/II clinical trial in Australia.[1]It was originally developed at theInstitute of Protein Design(IPD) and the University of Washington School of Medicine, both based at theUniversity of Washington.[2][3][4]

Part ofa serieson the
COVID-19 pandemic
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
Timeline
2019
2020
2021
2022
2023
Locations
By country and territory
By conveyance
International response
National responses
Medical response
Vaccines
Current vaccines
Variants
Variants of concern
Other variants
Economic impactandrecession
By country
By sport
Impacts
Long COVID
Society
Politics
virus iconCOVID-19 portal

References

[edit]
  1. ^"ANZCTR - Registration".anzctr.org.au.Retrieved18 August2021.
  2. ^"Icosavax Initiates Phase 1/2 Trial of COVID-19 VLP Vaccine Candidate - Icosavax, Inc".investors.icosavax.Archived fromthe originalon 30 October 2021.Retrieved18 August2021.
  3. ^"Two nanoparticle vaccines enter clinical trials".Institute for Protein Design.2 June 2021.Retrieved18 August2021.
  4. ^Arunachalam PS, Walls AC, Golden N, Atyeo C, Fischinger S, Li C, et al. (June 2021)."Adjuvanting a subunit COVID-19 vaccine to induce protective immunity".Nature.594(7862): 253–258.Bibcode:2021Natur.594..253A.doi:10.1038/s41586-021-03530-2.PMID33873199.
Stub icon

This article about COVID-19 vaccines is astub.You can help Wikipedia byexpanding it.

Stub icon

This article aboutvaccinesorvaccinationis astub.You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=IVX-411&oldid=1243012742"